Literature DB >> 33667232

Clinical and immunological characteristics of tegumentary leishmaniasis cases in Bolivia.

Cristina Ballart1,2, Mary Cruz Torrico3,4, Gisela Vidal3, Faustino Torrico3,4, Daniel Lozano3,4, Montserrat Gállego1,2, Lilian Pinto3, Ernesto Rojas4, Ruth Aguilar1, Carlota Dobaño1, Sonia Ares-Gomez1, Albert Picado1,5.   

Abstract

BACKGROUND: Tegumentary leishmaniasis (TL) is a parasitic disease that can present a cutaneous or mucocutaneous clinical form (CL and MCL, respectively). The disease is caused by different Leishmania species and transmitted by phlebotomine sand flies. Bolivia has one of the highest incidences of the disease in South America and the diagnosis is done by parasitological techniques. Our aim was to describe the clinical and immunological characteristics of CL and MCL patients attending the leishmaniasis reference center in Cochabamba, Bolivia, in order to gain updated clinical and epidemiological information, to evaluate the diagnostic methods used and to identify biomarkers related to clinical disease and its evolution. METHODOLOGY/PRINCIPAL
FINDINGS: The study was conducted from September 2014 to November 2015 and 135 patients with lesions compatible with CL or MCL were included. Epidemiological and clinical data were collected using a semi-structured questionnaire. Two parasitological diagnostic methods were used: Giemsa-stained smears and culture of lesion aspirates. Blood samples obtained from participants were used to measure the concentrations of different cytokines. 59.2% (80/135) were leishmaniasis confirmed cases (CL: 71.3%; MCL: 28.7%). Sixty percent of the confirmed cases were positive by smears and 90.6% were positive by culture. 53.8% were primo-infections. Eotaxin and monokine induced by IFN-γ presented higher serum concentrations in the MCL clinical presentation compared to CL cases and no-cases. None of the cytokines presented different concentrations between primo-infections and secondary infections due to treatment failure.
CONCLUSIONS/SIGNIFICANCE: In Bolivia, parasitological diagnosis remains the reference standard in diagnosis of leishmaniasis because of its high specificity, whereas the sensitivity varies over a wide range leading to loss of cases. Until more accurate tools are implemented, all patients should be tested by both smears and culture of lesion aspirates to minimize the risk of false negatives. Our results showed higher concentrations of several cytokines in MCL compared to CL, but no differences were observed between CL and no-cases. In addition, none of the cytokines differed between primary and secondary infections. These results highlight the need of further research to identify biomarkers of susceptibility and disease progression, in addition to looking at the local cellular immune responses in the lesions.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33667232      PMCID: PMC7968743          DOI: 10.1371/journal.pntd.0009223

Source DB:  PubMed          Journal:  PLoS Negl Trop Dis        ISSN: 1935-2727


  41 in total

Review 1.  Leishmaniasis in the major endemic region of Plurinational State of Bolivia: Species identification, phylogeography and drug susceptibility implications.

Authors:  Pablo Bilbao-Ramos; M Auxiliadora Dea-Ayuela; Oscar Cardenas-Alegría; Efraín Salamanca; José Antonio Santalla-Vargas; Cesar Benito; Ninoska Flores; Francisco Bolás-Fernández
Journal:  Acta Trop       Date:  2017-07-24       Impact factor: 3.112

2.  Leishmania major Infection-Induced VEGF-A/VEGFR-2 Signaling Promotes Lymphangiogenesis That Controls Disease.

Authors:  Tiffany Weinkopff; Christoph Konradt; David A Christian; Dennis E Discher; Christopher A Hunter; Phillip Scott
Journal:  J Immunol       Date:  2016-07-29       Impact factor: 5.422

3.  Generic sodium stibogluconate is as safe and effective as branded meglumine antimoniate, for the treatment of tegumentary leishmaniasis in Isiboro Secure Park, Bolivia.

Authors:  H Bermúdez; E Rojas; L Garcia; P Desjeux; J-C Dujardin; M Boelaert; F Chappuis
Journal:  Ann Trop Med Parasitol       Date:  2006-10

Review 4.  Leishmaniases in Bolivia: comprehensive review and current status.

Authors:  Ana L García; Rudy Parrado; Ernesto Rojas; Raúl Delgado; Jean-Claude Dujardin; Richard Reithinger
Journal:  Am J Trop Med Hyg       Date:  2009-05       Impact factor: 2.345

5.  Clinical and parasite species risk factors for pentavalent antimonial treatment failure in cutaneous leishmaniasis in Peru.

Authors:  Alejandro Llanos-Cuentas; Gianfranco Tulliano; Roger Araujo-Castillo; Cesar Miranda-Verastegui; Giovanna Santamaria-Castrellon; Luis Ramirez; Marcela Lazo; Simonne De Doncker; Marleen Boelaert; Jo Robays; Jean-Claude Dujardin; Jorge Arevalo; Francois Chappuis
Journal:  Clin Infect Dis       Date:  2008-01-15       Impact factor: 9.079

Review 6.  Eosinophils and mast cells in leishmaniasis.

Authors:  Nilda E Rodríguez; Mary E Wilson
Journal:  Immunol Res       Date:  2014-08       Impact factor: 2.829

7.  Leishmaniasis worldwide and global estimates of its incidence.

Authors:  Jorge Alvar; Iván D Vélez; Caryn Bern; Mercé Herrero; Philippe Desjeux; Jorge Cano; Jean Jannin; Margriet den Boer
Journal:  PLoS One       Date:  2012-05-31       Impact factor: 3.240

8.  Leishmaniasis in Chaparé, Bolivia.

Authors:  Ernesto Rojas; Rudy Parrado; Raúl Delgado; Richard Reithinger; Ana L Garcia
Journal:  Emerg Infect Dis       Date:  2009-04       Impact factor: 6.883

9.  Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth.

Authors:  F Bussolino; M F Di Renzo; M Ziche; E Bocchietto; M Olivero; L Naldini; G Gaudino; L Tamagnone; A Coffer; P M Comoglio
Journal:  J Cell Biol       Date:  1992-11       Impact factor: 10.539

10.  Risk factors for cutaneous leishmaniasis in the rainforest of Bolivia: a cross-sectional study.

Authors:  Daniel Eid; Miguel Guzman-Rivero; Ernesto Rojas; Isabel Goicolea; Anna-Karin Hurtig; Daniel Illanes; Miguel San Sebastian
Journal:  Trop Med Health       Date:  2018-04-17
View more
  2 in total

1.  Disruption of cellular immune response among male rotating night shift workers in Spain- The HORMONIT study.

Authors:  Barbara N Harding; Ruth Aguilar; Ana Espinosa; Gemma Castaño-Vinyals; Kyriaki Papantoniou; José Maria Navarrete; Patricia Such Faro; Antonio Torrejón; Carlota Dobaño; Gemma Moncunill; Manolis Kogevinas
Journal:  Front Immunol       Date:  2022-09-02       Impact factor: 8.786

2.  Maternal and neonatal immune response to SARS-CoV-2, IgG transplacental transfer and cytokine profile.

Authors:  Rocío Rubio; Ruth Aguilar; Mariona Bustamante; Erica Muñoz; Miquel Vázquez-Santiago; Rebeca Santano; Marta Vidal; Natalia Rodrigo Melero; Daniel Parras; Pau Serra; Pere Santamaria; Carlo Carolis; Luis Izquierdo; Maria Dolores Gómez-Roig; Carlota Dobaño; Gemma Moncunill; Edurne Mazarico
Journal:  Front Immunol       Date:  2022-09-27       Impact factor: 8.786

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.